Literature DB >> 26464233

Clinical and laboratory associations of severity in a Sri Lankan cohort of patients with serologically confirmed leptospirosis: a prospective study.

Senaka Rajapakse1, Praveen Weeratunga2, M J Roshan Niloofa3, Narmada Fernando3, Chathuraka Rodrigo1, Sachith Maduranga1, Nipun Lakshitha de Silva1, Nipun Lakshitha Fernando1, H Janaka de Silva4, Lilani Karunanayake5, Shiroma Handunnetti3.   

Abstract

BACKGROUND: Leptospirosis results in significant morbidity and mortality. This study elucidates markers of severity in a cohort of Sri Lankan patients.
METHODS: Patients presenting to three healthcare institutions in the Western province of Sri Lanka with leptospirosis serological confirmed by the microscopic agglutination test (MAT) were included. Prospective data regarding demographic, clinical and laboratory parameters was extracted. Univariate associations and subsequent multivariate logistic regression models were constructed.
RESULTS: The study included 232 patients, with 68.5% (159) demonstrating severe disease. Significant associations of severe disease at a significance level of p<0.05 were fever >38.8°C on presentation, age >40 years, muscle tenderness, tachycardia on admission, highest white cell count >12 350/mm(3) and <7900/mm(3), highest neutrophil percentage >84%, haemoglobin >11.2 g/dL and <10.2 g/dL, packed cell volume (PCV) >33.8% and <29.8%, lowest platelet count <63 500/mm(3), highest alanine transaminase (ALT) >70 IU/L and hyponatremia with sodium <131 mEq/L. On multivariate analysis, PCV <29.8% (p=0.011; OR 3.750; CI: 1.394-10.423), ALT >70 IU/L (p=0.044; OR 2.639; CI: 1.028-6.774) and hyponatremia <131 mEq/L (p=0.019; OR 6.413; CI: 1.353-30.388) were independent associations of severe disease.
CONCLUSIONS: Severity associations were demonstrated with both clinical and laboratory parameters. There is a need for novel biomarkers for prediction of severity in leptospirosis.
© The Author 2015. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Leptospirosis; Severity; Sri Lanka

Mesh:

Substances:

Year:  2015        PMID: 26464233     DOI: 10.1093/trstmh/trv079

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  6 in total

1.  Serial Changes in Complete Blood Counts in Patients with Leptospirosis: Our Experience.

Authors:  Deepa Sowkur Anandarama Adiga; Salony Mittal; Harini Venugopal; Sowmya Mittal
Journal:  J Clin Diagn Res       Date:  2017-05-01

2.  An Observational Study of Human Leptospirosis in Seychelles.

Authors:  Leon Biscornet; Jeanine de Comarmond; Jastin Bibi; Patrick Mavingui; Koussay Dellagi; Pablo Tortosa; Frédéric Pagès
Journal:  Am J Trop Med Hyg       Date:  2020-09       Impact factor: 2.345

3.  Estimating the burden of leptospirosis in Sri Lanka; a systematic review.

Authors:  Janith Warnasekara; Iresha Koralegedara; Suneth Agampodi
Journal:  BMC Infect Dis       Date:  2019-02-06       Impact factor: 3.090

4.  Hemostatic derangement in leptospirosis: A prospective cross-sectional study.

Authors:  Rasa Threeswaran; Nipun Lakshitha De Silva; Lallindra Gooneratne; Roopen Arya; Shiroma M Handunnetti; Senaka Rajapakse
Journal:  Int J Crit Illn Inj Sci       Date:  2020-09-16

5.  Clinical spectrum of endemic leptospirosis in relation to cytokine response.

Authors:  Niroshana J Dahanayaka; Suneth B Agampodi; Indika Seneviratna; Janith Warnasekara; Rukman Rajapakse; Kosala Ranathunga; Michael Matthias; Joseph M Vinetz
Journal:  PLoS One       Date:  2021-12-08       Impact factor: 3.240

6.  Protein Carbonyl as a Biomarker of Oxidative Stress in Severe Leptospirosis, and Its Usefulness in Differentiating Leptospirosis from Dengue Infections.

Authors:  Narmada Fernando; Shalini Wickremesinghe; Roshan Niloofa; Chaturaka Rodrigo; Lilani Karunanayake; H Janaka de Silva; A R Wickremesinghe; Sunil Premawansa; Senaka Rajapakse; Shiroma M Handunnetti
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.